Home - Forschungszentrum Borstel, Leibniz Lungenzentrum

die-lunge-im-fokus-fzb.jpg

Focus on the lungs

We are the lung research center of the Leibniz Association.
Our main focus: Common diseases such as asthma, allergies and chronic obstructive pulmonary disease (COPD), as well as infection-related inflammation of the lungs, in particular tuberculosis (TB).

Our Mission

die-lunge-im-fokus-fzb.jpg

Chronic lung diseases

The program area is dedicated to research into asthma, COPD and allergies, as these are among the most common chronic diseases and therefore cause an enormous burden for both patients and healthcare systems.

Priority Research Area

die-lunge-im-fokus-fzb.jpg

Infections

The Infections program area is dedicated to researching and combating bacterial infectious diseases of the lung with a focus on tuberculosis.
The aim is to improve the control and treatment of this disease.

To the program area

die-lunge-im-fokus-fzb.jpg

Science & Technology

This area combines overarching research units that are essential for research at the FZB and represent an important link between the subject areas.

Further Information

News

25.03.2025

Successful 2nd Edition of the “Bacterial Genome Sequencing Pan-European Network Conference” in Engelberg, Switzerland

A coalition of leading tuberculosis (TB) experts and medical societies is calling for an urgent expansion of the European Medicines Agency (EMA) label for pretomanid, a key drug in the fight against multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant TB (RR-TB). This appeal aligns with the latest World Health Organization (WHO) guidelines and aims to improve patient access
18.03.2025

Tuberculosis trends in Europe: Rising drug-resistant cases demand urgent action

A team of researchers from the Research Center Borstel in Germany, Imperial College London in the UK, and the European Centre for Disease Prevention and Control (ECDC) in Stockholm, Sweden, has analyzed tuberculosis notification rates across the European Union/European Economic Area (EU/EEA) from 2019 to 2023.
14.03.2025

Open letter: Experts urge urgent expansion of Pretomanid label to improve tuberculosis treatment access in Europe

A coalition of leading tuberculosis (TB) experts and medical societies is calling for an urgent expansion of the European Medicines Agency (EMA) label for pretomanid, a key drug in the fight against multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant TB (RR-TB). This appeal aligns with the latest World Health Organization (WHO) guidelines and aims to improve patient access to more